Incomplete Freund's adjuvant

Generic Name: Incomplete Freund's adjuvant

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: Y9DQK7DB5U

Associated Conditions: -

Associated Therapies: -

Clinical Trials

KLH Challenge to Explore the Human Immune Response

Not Applicable

Recruiting

Conditions: Immune Response

Interventions: Biological: Keyhole-Limpet Hemocyanin
Drug: Saline
Drug: Alhydrogel
Drug: Montanide ISA 51 VG

First Posted Date: 2023-05-25

Last Posted Date: 2023-05-25

Lead Sponsor: University of Oxford

Target Recruit Count: 39

Registration Number: NCT05876195

Locations: 🇬🇧
NIHR Oxford Experimental Medicine Clinical Research Facility, Oxford, United Kingdom

Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

Phase 2

Completed

Conditions: Recurrent Glioblastoma

Interventions: Drug: Pembrolizumab
Drug: SurVaxM
Drug: Sargramostim
Drug: Montanide ISA 51

First Posted Date: 2019-07-10

Last Posted Date: 2024-08-28

Lead Sponsor: David Peereboom

Target Recruit Count: 41

Registration Number: NCT04013672

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Phase 1

Recruiting

Conditions: Lung Atypical Carcinoid Tumor
Metastatic Pancreatic Neuroendocrine Tumor
Lung Typical Carcinoid Tumor

Interventions: Biological: Incomplete Freund's Adjuvant
Drug: Octreotide Acetate
Biological: Sargramostim
Biological: SVN53-67/M57-KLH Peptide Vaccine

First Posted Date: 2019-03-19

Last Posted Date: 2024-12-18

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 14

Registration Number: NCT03879694

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Phase 2

Active, not recruiting

Conditions: Glioblastoma
Gliosarcoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Montanide ISA 51 VG
Biological: Sargramostim
Biological: SVN53-67/M57-KLH Peptide Vaccine
Drug: Temozolomide

First Posted Date: 2015-05-28

Last Posted Date: 2024-03-01

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 66

Registration Number: NCT02455557

Locations: 🇺🇸
Dana-Farber Harvard Cancer Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 2 locations

Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission

Phase 1

Completed

Conditions: Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)

Interventions: Biological: WT1 126-134 peptide vaccine
Biological: basiliximab
Drug: Montanide ISA 51 VG
Drug: poly ICLC
Other: laboratory biomarker analysis

First Posted Date: 2013-04-29

Last Posted Date: 2018-03-09

Lead Sponsor: University of Chicago

Target Recruit Count: 7

Registration Number: NCT01842139

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery

Early Phase 1

Completed

Conditions: Recurrent Melanoma
Stage IIA Melanoma
Stage IIB Melanoma
Stage IIC Melanoma
Stage IIIA Melanoma
Stage IIIB Melanoma
Stage IIIC Melanoma
Stage IV Melanoma

Interventions: Drug: Montanide ISA 51 VG
Biological: MART-1 antigen
Other: laboratory biomarker analysis
Drug: resiquimod

First Posted Date: 2012-12-12

Last Posted Date: 2018-10-09

Lead Sponsor: Mayo Clinic

Target Recruit Count: 30

Registration Number: NCT01748747

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

Phase 1

Completed

Conditions: Melanoma (Skin)

Interventions: Biological: MART-1
Biological: NY-ESO-1
Drug: Montanide ISA 51 VG
Biological: BMS-936558

First Posted Date: 2010-08-06

Last Posted Date: 2023-01-18

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 127

Registration Number: NCT01176461

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

Phase 2

Completed

Conditions: Skin Cancer
Melanoma

Interventions: Drug: Montanide ISA 51 VG
Procedure: Radiation
Drug: Aldesleukin
Drug: Fludarabine
Drug: Cyclophosphamide
Genetic: Anti-MART-1 F5 TCR PBL

First Posted Date: 2009-06-18

Last Posted Date: 2015-10-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 4

Registration Number: NCT00923195

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Phase 2

Completed

Conditions: Iris Melanoma
Stage IIC Melanoma
Stage IV Melanoma
Extraocular Extension Melanoma
Stage IIIC Melanoma
Ciliary Body and Choroid Melanoma, Medium/Large Size
Stage IIB Melanoma
Stage IIIA Melanoma
Stage IIIB Melanoma

Interventions: Biological: tyrosinase peptide
Biological: gp100 antigen
Biological: MART-1 antigen
Biological: incomplete Freund's adjuvant
Drug: Montanide ISA 51 VG
Biological: sargramostim
Other: laboratory biomarker analysis

First Posted Date: 2004-08-05

Last Posted Date: 2015-04-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00089063

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Phase 2

Completed

Conditions: Recurrent Intraocular Melanoma
Recurrent Melanoma
Stage IIIC Melanoma
Ciliary Body and Choroid Melanoma, Small Size
Stage IIIA Melanoma
Stage IIIB Intraocular Melanoma
Extraocular Extension Melanoma
Iris Melanoma
Ciliary Body and Choroid Melanoma, Medium/Large Size
Stage IIIB Melanoma

Interventions: Biological: gp100 antigen
Biological: tyrosinase peptide
Biological: recombinant MAGE-3.1 antigen
Biological: multi-epitope melanoma peptide vaccine
Biological: incomplete Freund's adjuvant
Drug: Montanide ISA 51 VG
Drug: agatolimod sodium
Other: laboratory biomarker analysis

First Posted Date: 2004-06-11

Last Posted Date: 2014-05-22

Lead Sponsor: University of Southern California

Target Recruit Count: 42

Registration Number: NCT00085189

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy